Adiponectin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Adiponectin is a hormone your fat makes, and it falls as you gain fat. Many studies link low levels to diabetes. It has never been given to a person. Gene studies in up to 80,000 people do not back the idea that low adiponectin causes insulin resistance or diabetes. In older adults, higher levels go with dying sooner.
Evidence grade for Adiponectin: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 3 human studies where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
3 human studies where nobody was given it
2 effects reported, 2 unwanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Ageing and longevity, Heart and circulation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Adiponectin is a hormone your fat makes. Unlike most fat hormones, it goes down as you gain fat. Low levels go with diabetes, so people call it the good fat hormone. Nobody has ever given it to a person.
What people take it for
- Better insulin and blood sugar.
- Living longer.
- A reason to try the research chemical AdipoRon.
What studies in people showed
Nobody has given adiponectin or AdipoRon to a person. Since nobody can patent the hormone, nobody is likely to pay for that study. What we have are gene studies and studies that watch people. In up to 80,000 people, those born with genes for lower adiponectin did not get more diabetes. So low adiponectin looks like a result, not a cause. In older adults, higher levels went with dying sooner, not later. In 356 people with type 2 diabetes, genes for higher adiponectin went with more heart deaths. The blood sugar and longer life effects of AdipoRon are in mice.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- AdipoRon has never been given to a person, so there is no safety data.
- Higher adiponectin goes with more deaths in older people and heart patients, and nobody knows why.
Where these come from: No user reports. These come from the gene studies and the heart health studies on this page.
My bottom line
Raising adiponectin has no human reason behind it. If your blood sugar is off, work on your waist and your fasting insulin. Check both in your blood work.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Adiponectin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Blood sugar and insulin31,356 people · 2 studies
- Living longer356 people · 2 studies
- Heart attacks and strokesno headcount stated · 1 study
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Cell energy and mitochondria2 animal or lab studies
32 of the 36 indexed goals have no study of any kind behind Adiponectin
No study in people, animals or cells on this page reports a result for these. That does not prove Adiponectin does nothing for them. It does mean anything you have heard about Adiponectin and one of these did not come from a study cited here.
Show full evidence
What is Adiponectin?
Adiponectin is a hormone your fat makes, and it falls as you gain fat. Many studies link low levels to diabetes. It has never been given to a person. Gene studies in up to 80,000 people do not back the idea that low adiponectin causes insulin resistance or diabetes. In older adults, higher levels go with dying sooner.
Adiponectin is a protein made by fat cells. There is a lot of it in the blood, in clumps of different sizes. Most fat hormones go up as you gain fat. This one goes down. In studies that simply measure people, low adiponectin goes hand in hand with insulin resistance, type 2 diabetes and heart disease. That link is the whole reason for the popular claim that adiponectin is the good fat hormone, and that raising it would help.
Nobody has ever given lab-made adiponectin to a person in any study we could find. No adiponectin drug exists. No drug that switches on its receptors has been tested in people. We searched PubMed for human studies of the research chemical AdipoRon on 11 September 2026 and found none. So all the human evidence comes from watching people and from genes. The gene evidence cuts against the story.
A 2013 study used natural gene differences as a test. The idea is simple. If low adiponectin causes diabetes, people born with genes for low adiponectin should get more diabetes. It covered up to 31,000 people for blood sugar and fat measures. 2,969 of them had the best test of how well insulin works. And 15,960 people with diabetes were compared with 64,731 without. Just measuring the hormone, lower adiponectin went with 1.75 times the odds of diabetes. But people born with genes for lower adiponectin had no higher fasting insulin. Their diabetes risk was no higher either (odds 0.94, with a range from 0.75 to 1.19). A hint about insulin did not hold up on a second method. The authors found no steady evidence that raising adiponectin would help insulin or diabetes risk.
The death data point the wrong way for a protective hormone. The Cardiovascular Health Study followed older adults. In those without heart disease, the risk of death dropped as adiponectin rose up to 12.4 mg/L. Above that, the risk climbed again. In those with heart disease alone, there was no link. In those with heart failure or an irregular heartbeat, higher adiponectin meant a higher risk of death, 1.31 times for each step up. A gene study in 356 patients with type 2 diabetes found that genes for higher adiponectin went with 1.94 times as many deaths from heart disease. That suggests the pattern is real, not a quirk of the data. Why it happens is argued over. It could be the body making more to make up for illness. It could be the body ignoring the hormone. Or it could be direct harm. We present it as disputed.
All the treatment work is in mice. That includes finding the receptors in 2003. It also includes AdipoRon, a pill-type molecule that switches on both receptors. In obese mice, it improved blood sugar handling. In a strain of diabetic mice on a high-fat diet, it lengthened their shortened lifespan. AdipoRon is sold as a research chemical with no human safety data.
How does Adiponectin work?
In people, adiponectin runs low when body fat, insulin resistance and diabetes run high. But gene studies do not show that the adiponectin level causes changes in insulin or diabetes. In older adults and people with heart disease, higher adiponectin goes with a higher risk of death. No one has shown how it works in a person, because no one has changed adiponectin in a person to see what happens. In mice and in a dish, adiponectin docks on two receptors, AdipoR1 and AdipoR2, and a third partner called T-cadherin. AdipoR1 works mainly through a fuel sensor called AMPK. AdipoR2 works mainly through a fat-burning switch called PPAR-alpha. Together they raise fat burning in muscle and liver and help insulin work. The large clumps of adiponectin are the form most often reported to be active. AdipoRon copies these effects in mice. It stops working in mice missing both receptors.
What have studies in people found about Adiponectin?
No person has been given adiponectin, or a drug that switches on its receptors, in any study we could find. The human record comes from watching people and from gene studies. The gene studies do not back the cause-and-effect story that the watching studies suggested.
- Gene study (Diabetes 2013): up to 31,000 people for blood sugar and fat measures, 2,969 with the best insulin test, and 15,960 people with diabetes against 64,731 without. People born with genes for lower adiponectin did not have higher fasting insulin or more diabetes (odds 0.94).
- Cardiovascular Health Study (Circulation 2012), older adults: without heart disease, the risk of death rose again above 12.4 mg/L (1.19 times for each step up). With heart failure or an irregular heartbeat, higher adiponectin meant more deaths (1.31 times for each step up).
- Gargano Heart Study (Cardiovasc Diabetol 2016): 356 people with type 2 diabetes. Genes for higher adiponectin went with more deaths from heart disease (1.94 times).
- PubMed, searched 11 September 2026: no human study of AdipoRon. US trials register: no study giving lab-made adiponectin or AdipoRon.
What this does not tell you: Studies that watch people cannot tell you what raising or lowering adiponectin would do. The gene studies come closest. They say it would do nothing you could detect for insulin resistance or diabetes. The link with death shows up again and again in older people and heart patients. But nobody agrees why. The body making more to make up for illness, the body ignoring the hormone, or direct harm would each give the same pattern. None of the human data says anything about adiponectin supplements, because there are none. None says anything about AdipoRon, because nobody has ever given it to a person. Anyone using AdipoRon is the first human safety test of it.
The state of the research
Adiponectin is the clearest case on this site of watching studies running ahead of the proof. Hundreds of papers report that low adiponectin comes with obesity, insulin resistance, diabetes and heart disease. Finding the receptors in 2003 gave that link a mechanism in mice. The natural conclusion is that adiponectin protects you and raising it would help. That is what most peptide and supplement pages say. The 2013 gene study tested that conclusion in tens of thousands of people. It came from a large group of researchers paid by the NIH, and it could not back the conclusion. Genes that lower adiponectin do not raise diabetes risk. The point is not that adiponectin does nothing. The point is that its level is at least as much a result of your metabolism as a cause of it. There is no human reason to try to raise it.
The death link is the other half of the correction, and it is a real argument. In the Cardiovascular Health Study, higher adiponectin predicted death in older adults with heart problems. One small Italian gene study argues this is cause and effect. The other side says a failing heart releases hormones called natriuretic peptides, which push adiponectin up as a sign of how sick someone is. The reviews we cite make that case. A 2020 review questions whether the pattern even holds in stable heart disease. We present both sides and do not choose. What nobody disputes is that there are no treatment studies. No company has an adiponectin drug. The receptor drug AdipoRon has been in mice since 2013 without a registered human study. And the longer life it gave mice was a rescue of a diabetic strain on a high-fat diet, not longer life in normal animals. Anyone selling AdipoRon on the adiponectin story is stretching from mice across a gap that the human gene studies call into question.
The evidence, in charts
Fig. 1a · how many people
31,356people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| Diabetes 2013 | 31,000 | 99% |
| Cardiovascular Diabetology 2016 | 356 | 1% |
One study holds 99% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 9 sources here are studies in people. The rest are not.
- Study in people · done in people333%
- Animal study · done in animals222%
- Review of studies · sums up other studies444%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 6 different years, 2003 to 2020, counted from the list of sources on this page. The newest source on file is from 2020, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- 26,414 Da precursor (244 residues, UniProt Q15848); mature chain residues 19 to 244, 226 amino acids, circulating as trimers, hexamers and high molecular weight multimers
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Adiponectin, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2013Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes
Adiponectin looks protective until you use genetics to test it, and then the link disappears. Inherited variants in up to 31,000 people were used as a natural experiment. Simply measuring the hormone, lower adiponectin went with higher fasting insulin and clearly higher diabetes risk. Being born with genetically lower adiponectin showed no such link, on either measure. The authors found no consistent evidence that raising adiponectin would improve insulin sensitivity or diabetes risk. The NIH paid for it.
ADIPOQ variants as instruments in up to 31,000 people, 2,969 with gold-standard insulin sensitivity, 15,960 diabetes cases and 64,731 controls. Observationally, 1 SD lower adiponectin went with 0.31 SD higher fasting insulin and diabetes odds of 1.75. Genetically lower adiponectin showed no association with fasting insulin (0.02 SD, 95 percent CI -0.07 to 0.11) or diabetes (OR 0.94, 0.75 to 1.19; genetic risk score OR 0.99 per allele). The authors found no consistent evidence that raising adiponectin would improve insulin sensitivity or diabetes risk. NIH funded.
- Study in people2012Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study
More adiponectin is not better, and above a point it goes with dying sooner. In older adults free of heart disease, the risk of death fell as adiponectin rose up to a middling level, then climbed again above it. In people who already had heart failure or an irregular heartbeat, higher adiponectin went with clearly higher death rates. Nobody was given anything. This is a group watched over time, and it undercuts the idea of raising this hormone on purpose. The NIH paid for it.
Population-based cohort of older adults. In those free of cardiovascular disease, the association with all-cause mortality was U-shaped: hazard ratio 0.81 per SD up to 12.4 mg/L, then 1.19 per SD (95 percent CI 1.12 to 1.27) above it. No association in those with cardiovascular disease alone; in heart failure or atrial fibrillation, higher adiponectin meant higher mortality, hazard ratio 1.31 (1.15 to 1.50) after adjustment. Results were similar for high molecular weight adiponectin and cardiovascular death. NIH funded.
- Study in people2016Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes
Genetics points the harm the wrong way for anyone hoping to raise adiponectin. 356 people with type 2 diabetes in Italy were followed for about five and a half years, and 58 died of heart disease. Those carrying a gene variant that raises adiponectin died of heart disease about twice as often. The genetic signal was stronger than the plain observed one, which the authors read as evidence the paradox is real. Public money paid for it.
Gargano Heart Study, 356 patients with type 2 diabetes, mean follow-up 5.4 years, 58 cardiovascular deaths. The ADIPOQ variant rs822354 raised adiponectin and was associated with cardiovascular mortality (incidence rate ratio 1.94, 95 percent CI 1.23 to 3.07), with a genetic effect larger than the observational one, interpreted by the authors as evidence that the paradoxical association is causal. Non-US government funded.
- Review of studies2020Is There Really an Association of High Circulating Adiponectin Concentration and Mortality or Morbidity Risk in Stable Coronary Artery Disease?
A review that questions how solid the link between high adiponectin and death is in people with stable heart disease, and what else might explain it. It is one side of a live argument.
Review questioning how robust the adiponectin mortality paradox is in stable coronary disease and what confounding it might reflect; one side of a live dispute.
- Review of studies2020Insights Into the Controversial Aspects of Adiponectin in Cardiometabolic Disorders
A review that sets out the competing reasons high adiponectin might go with harm. The body could be making more to make up for illness, or ignoring it. Heart hormones could push it up in heart failure. Or it could do direct harm. The review does not settle which.
Review setting out the competing explanations for high adiponectin predicting harm: compensatory secretion, adiponectin resistance, natriuretic peptide driven release in heart failure, or direct effects. Does not resolve them.
- Review of studies2005Adiponectin and adiponectin receptors
An early review of adiponectin's biology and the links seen in people. It was written before the gene studies and the death data.
Foundational review of adiponectin biology, multimer forms, receptors and the observational human associations, written before the Mendelian randomisation and mortality paradox data.
- Review of studies2013Adiponectin receptor as a key player in healthy longevity and obesity-related diseases
A review from the AdipoRon team. It pitches switching on adiponectin receptors as a way to live longer, based on mouse work and research on eating less.
Review from the AdipoRon group framing adiponectin receptor agonism as a longevity strategy, on the strength of mouse and calorie restriction data.
- Animal study2003Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
In mouse cells and tissues. This paper found adiponectin's two receptors, AdipoR1 and AdipoR2. It showed they carry adiponectin's effects on fat burning and sugar uptake.
Identification of AdipoR1 and AdipoR2 and demonstration in mouse cells and tissues that they mediate adiponectin's effects on fatty acid oxidation and glucose uptake through AMPK and PPAR-alpha.
- Animal study2013A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
In mice. AdipoRon, a pill-type molecule, switched on both adiponectin receptors. It helped insulin work and improved blood sugar handling in mice on a high-fat diet. It did nothing in mice missing both receptors. It eased diabetes in a diabetic strain and lengthened their shortened lifespan. Mouse only. There is no human data.
AdipoRon, an oral small molecule binding AdipoR1 and AdipoR2, activated AMPK and PPAR-alpha, improved insulin resistance and glucose tolerance in mice on a high-fat diet (abolished in double knockouts), ameliorated diabetes in db/db mice and prolonged their shortened lifespan on a high-fat diet. Mouse only; no human data exist.
Common questions
Has Adiponectin been tested in people?
Not in a completed trial cited here. 3 human studies where nobody was given it. Adiponectin is a hormone your fat makes, and it falls as you gain fat. Many studies link low levels to diabetes. It has never been given to a person. Gene studies in up to 80,000 people do not back the idea that low adiponectin causes insulin resistance or diabetes. In older adults, higher levels go with dying sooner.
What is the Adiponectin dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 3 human studies where nobody was given it
Is Adiponectin FDA-approved?
Not FDA-approved. No adiponectin product, and no drug that switches on its receptor, is approved or has been tested in a registered human study. AdipoRon has never been tested in people.
Is low adiponectin the cause of insulin resistance?
It goes with it, strongly. In studies that simply measure people, each step lower in adiponectin goes with 1.75 times the odds of diabetes. But a gene study in up to 80,000 people found something else. People born with genes for lower adiponectin did not have higher fasting insulin or more diabetes (odds 0.94). The gene evidence does not back it as a cause. The authors said raising adiponectin would not be expected to help.
Is high adiponectin good?
Not simply. In older adults without heart disease, the link with death was U-shaped. The risk went up again above about 12.4 mg/L. In people with heart failure or an irregular heartbeat, higher adiponectin meant a higher risk of death, 1.31 times for each step up. Whether that is a sign of illness or a cause of harm is argued over and not settled.
Can I take adiponectin or AdipoRon?
No adiponectin product exists, and lab-made adiponectin has never been given to a person. AdipoRon, the pill-type receptor drug, has only been studied in mice since 2013. There is no registered human study and no human safety data. It is sold as a research chemical.
Does adiponectin extend lifespan?
AdipoRon lengthened the shortened lifespan of diabetic mice on a high-fat diet. That is a rescue in a sick strain, not longer life in normal animals. There is no human data on longer life. In older people, higher adiponectin goes with shorter survival.